Astria Therapeutics Inc News

Astria Therapeutics Analyst Ratings

BenzingaMay 21 08:03 ET

Astria Therapeutics Analyst Ratings

BenzingaMay 10 09:37 ET

Astria Therapeutics Analyst Ratings

BenzingaApr 23 06:22 ET

Astria Therapeutics Analyst Ratings

BenzingaMar 25 12:36 ET

Astria Therapeutics Analyst Ratings

BenzingaMar 14 07:14 ET

Astria Therapeutics Analyst Ratings

BenzingaMar 5 07:07 ET

Astria Therapeutics Analyst Ratings

BenzingaJan 30 11:01 ET

Astria Therapeutics Analyst Ratings

BenzingaNov 15, 2023 13:10 ET

Oppenheimer Adjusts Astria Therapeutics Price Target to $25 From $30, Maintains Outperform Rating

MT NewswiresNov 15, 2023 09:12 ET

Wedbush Trims Astria Therapeutics' Price Target to $17 From $18, Keeps Outperform Rating

MT NewswiresNov 13, 2023 12:01 ET

Wedbush Maintains Outperform on Astria Therapeutics, Lowers Price Target to $18

BenzingaOct 13, 2023 11:22 ET

Astria Therapeutics Analyst Ratings

BenzingaOct 13, 2023 11:21 ET

HC Wainwright & Co. Maintains Buy on Astria Therapeutics, Lowers Price Target to $18

BenzingaOct 12, 2023 07:06 ET

Astria Therapeutics Analyst Ratings

BenzingaOct 12, 2023 07:02 ET

Wedbush Trims Astria Therapeutics' Price Target to $25 From $26, Keeps Outperform Rating

MT NewswiresAug 8, 2023 07:09 ET

Astria Therapeutics Analyst Ratings

BenzingaAug 8, 2023 06:30 ET

Oppenheimer Reiterates Outperform on Astria Therapeutics, Maintains $30 Price Target

BenzingaJun 8, 2023 07:52 ET

HC Wainwright & Co. Reiterates Buy on Astria Therapeutics, Maintains $20 Price Target

BenzingaMay 12, 2023 06:30 ET

Evercore ISI Group Initiates Coverage On Astria Therapeutics With Outperform Rating, Announces Price Target of $18

BenzingaMar 28, 2023 07:12 ET

Wedbush Adjusts Price Target on Astria Therapeutics to $26 From $27, Keeps Outperform Rating

MT NewswiresMar 22, 2023 10:57 ET